<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01930058</url>
  </required_header>
  <id_info>
    <org_study_id>8876-003</org_study_id>
    <secondary_id>2013-002566-39</secondary_id>
    <nct_id>NCT01930058</nct_id>
  </id_info>
  <brief_title>Safety, Pharmacokinetics, and Pharmacodynamics of MK-8876 in Participants With Hepatitis C Infection (MK-8876-003)</brief_title>
  <official_title>A Multiple Dose Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of MK-8876 in Hepatitis C Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This adaptive design study will evaluate the safety, pharmacokinetics, and effect on
      hepatitis C virus (HCV) RNA levels of multiple doses of MK-8876 in participants with HCV
      infection. The study will consist of 4 parts evaluating participants infected with specific
      hepatitis C virus genotypes and up to 10 panels allowing for additional participants to
      enroll in each panel as specified in the study analysis. The hypothesis evaluated in the
      study is that a ≥2.5 log IU/mL reduction in HCV RNA from Baseline will accompany multiple
      dose administration of MK-8876 in participants with HCV infection.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change From Baseline in HCV Viral Load</measure>
    <time_frame>Baseline and Day 7</time_frame>
    <description>The mean change (log10) in HCV ribonucleic acid (RNA) from baseline to Day 7 was determined for each panel of participants.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From Time Zero to 24 Hours (hr) Post-dose (AUC0-24 hr) of MK-8876</measure>
    <time_frame>Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, and 24 hours post-dose on Days 1 and 7</time_frame>
    <description>AUC0-24hr is a measure of the mean concentration of drug in plasma after dosing to 24 hr post-dose. Plasma AUC0-24hr was calculated on Day 1 and Day 7 of MK-8876 dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of MK-8876</measure>
    <time_frame>Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, and 24 hours post-dose on Days 1 and 7</time_frame>
    <description>Cmax is a measure of the maximum plasma concentration of drug post-dose. Plasma Cmax was determined on Day 1 and Day 7 of MK-8876 dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Plasma Concentration (C24hr) of MK-8876</measure>
    <time_frame>24 hours post-dose on Days 1 and 7</time_frame>
    <description>C24hr is a measure of the plasma drug concentration 24 hours post-dose (i.e., trough concentration). Plasma C24hr was determined on Day 1 and Day 7 of MK-8876 dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Plasma Concentration (Tmax) of MK-8876</measure>
    <time_frame>Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, and 24 hours post-dose on Days 1 and 7</time_frame>
    <description>Tmax is a measure of time required to reach the maximum plasma drug concentration post-dose. Plasma Tmax was calculated on Day 1 and Day 7 of MK-8876 dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Terminal Plasma Half-life (t½) of MK-8876</measure>
    <time_frame>Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, and 24 hours post-dose on Day 7</time_frame>
    <description>t½ is the time required for the maximum plasma drug concentration to reduce by 50% post-dose. Plasma t½ was determined on Day 7 of MK-8876 dosing.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Panel A: HCV GT3 MK-8876 150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants infected with HCV GT3 received 150 mg MK-8876 once daily (q.d.) by mouth for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel B: HCV GT3 MK-8876 800 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants infected with HCV GT3 received 800 mg MK-8876 q.d. by mouth for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel E: HCV GT1a MK-8876 800 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants infected with HCV GT1a received 800 mg MK-8876 q.d. by mouth for 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-8876</intervention_name>
    <description>MK-8876 10 mg or 100 mg tablets taken q.d. by mouth.</description>
    <arm_group_label>Panel A: HCV GT3 MK-8876 150 mg</arm_group_label>
    <arm_group_label>Panel B: HCV GT3 MK-8876 800 mg</arm_group_label>
    <arm_group_label>Panel E: HCV GT1a MK-8876 800 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  is male, or female of non-childbearing potential (non-childbearing potential is
             defined as postmenopausal without menses for ≥1 year or after medically documented
             hysterectomy, oophorectomy, or tubal ligation)

          -  agrees to use a medically acceptable method of contraception through 90 days after the
             last dose of study drug if participant has a female partner of childbearing potential
             must (males should use a condom and their partner of childbearing potential must use
             hormonal contraception, intrauterine device, diaphragm, cervical cap, or female
             condom)

          -  has a body mass index (BMI) between 18 and 37 kg/m^2

          -  has a clinical diagnosis of chronic HCV infection defined by positive serology for HCV
             for ≥6 months

          -  agrees to follow the smoking and other trial restrictions

        Exclusion Criteria:

          -  is mentally or legally institutionalized or incapacitated, has significant emotional
             problems at study start or has clinically significant psychiatric disorder of the last
             5 years

          -  has a history of clinically significant endocrine, gastrointestinal (except HCV
             infection), cardiovascular, hematological, hepatic, immunological, renal, respiratory,
             or genitourinary abnormalities or diseases

          -  has a history of stroke, chronic seizures, or major neurological disorder

          -  has a history of cancer (except adequately treated non-melanomatous skin carcinoma,
             carcinoma in situ of the cervix, or other malignancies which have been successfully
             treated for ≥10 years

          -  has a history of significant multiple and/or severe allergies or has had an
             anaphylactic reaction or significant intolerability to drugs or food

          -  has a history of clinically significant hepatic disease, Gilbert's disease, biliary
             tract disease, or human immunodeficiency virus

          -  has had major surgery or donated or lost &gt;1 unit of blood within 4 weeks before the
             study

          -  has participated in another investigational trial within 4 weeks before the study

          -  Is unable to refrain from or anticipates the use of any medication from 2 weeks before
             the study and throughout the study

          -  consumes &gt;2 glasses of alcoholic beverages per day

          -  consumes &gt;6 servings (1 serving is ~120 mg caffeine) of coffee, tea, cola, energy
             drinks, or other caffeinated beverages per day

          -  is a regular user of any illicit drugs or history of drug abuse within 12 months of
             the study

          -  has evidence or history of chronic hepatitis not caused by HCV (except acute
             non-HCV-related hepatitis that resolved &gt;6 months before the study)

          -  has previously received treatment with another HCV non-nucleoside inhibitor (previous
             use of other HCV investigational therapies or marketed compounds is permitted if
             treatment ended ≥3 months before the study)

          -  has clinical or laboratory evidence of advanced or decompensated liver disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Germany</country>
    <country>Moldova, Republic of</country>
  </removed_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 23, 2013</study_first_submitted>
  <study_first_submitted_qc>August 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2013</study_first_posted>
  <results_first_submitted>November 11, 2015</results_first_submitted>
  <results_first_submitted_qc>January 5, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 4, 2016</results_first_posted>
  <last_update_submitted>March 10, 2017</last_update_submitted>
  <last_update_submitted_qc>March 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/study.html?id=8876-003&amp;kw=8876-003</doc_url>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Panel A: HCV GT3 MK-8876 150 mg</title>
          <description>Participants infected with HCV GT3 received 150 mg MK-8876 once daily (q.d.) by mouth for 7 days.</description>
        </group>
        <group group_id="P2">
          <title>Panel B: HCV GT3 MK-8876 800 mg</title>
          <description>Participants infected with HCV GT3 received 800 mg MK-8876 q.d. by mouth for 7 days.</description>
        </group>
        <group group_id="P3">
          <title>Panel E: HCV GT1a MK-8876 800 mg</title>
          <description>Participants infected with HCV GT1a received 800 mg MK-8876 q.d. by mouth for 7 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Panel A: HCV GT3 MK-8876 150 mg</title>
          <description>Participants infected with HCV GT3 received 150 mg MK-8876 q.d. by mouth for 7 days.</description>
        </group>
        <group group_id="B2">
          <title>Panel B: HCV GT3 MK-8876 800 mg</title>
          <description>Participants infected with HCV GT3 received 800 mg MK-8876 q.d. by mouth for 7 days.</description>
        </group>
        <group group_id="B3">
          <title>Panel E: HCV GT1a MK-8876 800 mg</title>
          <description>Participants infected with HCV GT1a received 800 mg MK-8876 q.d. by mouth for 7 days.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="3"/>
            <count group_id="B4" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32" spread="2.6"/>
                    <measurement group_id="B2" value="45" spread="12.5"/>
                    <measurement group_id="B3" value="49.7" spread="7.4"/>
                    <measurement group_id="B4" value="42.2" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in HCV Viral Load</title>
        <description>The mean change (log10) in HCV ribonucleic acid (RNA) from baseline to Day 7 was determined for each panel of participants.</description>
        <time_frame>Baseline and Day 7</time_frame>
        <population>All participants in Panels A, B, and E are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A: HCV GT3 MK-8876 150 mg</title>
            <description>Participants infected with HCV GT3 received 150 mg MK-8876 q.d. by mouth for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Panel B: HCV GT3 MK-8876 800 mg</title>
            <description>Participants infected with HCV GT3 received 800 mg MK-8876 q.d. by mouth for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>Panel E: HCV GT1a MK-8876 800 mg</title>
            <description>Participants infected with HCV GT1a received 800 mg MK-8876 q.d. by mouth for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in HCV Viral Load</title>
          <description>The mean change (log10) in HCV ribonucleic acid (RNA) from baseline to Day 7 was determined for each panel of participants.</description>
          <population>All participants in Panels A, B, and E are included in the analysis.</population>
          <units>Log10 change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.42" spread="0.12"/>
                    <measurement group_id="O2" value="-1.88" spread="0.5"/>
                    <measurement group_id="O3" value="-3.39" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration-time Curve From Time Zero to 24 Hours (hr) Post-dose (AUC0-24 hr) of MK-8876</title>
        <description>AUC0-24hr is a measure of the mean concentration of drug in plasma after dosing to 24 hr post-dose. Plasma AUC0-24hr was calculated on Day 1 and Day 7 of MK-8876 dosing.</description>
        <time_frame>Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, and 24 hours post-dose on Days 1 and 7</time_frame>
        <population>All participants in Panels A, B, and E are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A: HCV GT3 MK-8876 150 mg</title>
            <description>Participants infected with HCV GT3 received 150 mg MK-8876 q.d. by mouth for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Panel B: HCV GT3 MK-8876 800 mg</title>
            <description>Participants infected with HCV GT3 received 800 mg MK-8876 q.d. by mouth for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>Panel E: HCV GT1a MK-8876 800 mg</title>
            <description>Participants infected with HCV GT1a received 800 mg MK-8876 q.d. by mouth for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From Time Zero to 24 Hours (hr) Post-dose (AUC0-24 hr) of MK-8876</title>
          <description>AUC0-24hr is a measure of the mean concentration of drug in plasma after dosing to 24 hr post-dose. Plasma AUC0-24hr was calculated on Day 1 and Day 7 of MK-8876 dosing.</description>
          <population>All participants in Panels A, B, and E are included in the analysis.</population>
          <units>µM*hr</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="88.6"/>
                    <measurement group_id="O2" value="4.83" spread="26.1"/>
                    <measurement group_id="O3" value="10.7" spread="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.23" spread="113.7"/>
                    <measurement group_id="O2" value="23.1" spread="13.2"/>
                    <measurement group_id="O3" value="23.1" spread="22.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Plasma Concentration (Cmax) of MK-8876</title>
        <description>Cmax is a measure of the maximum plasma concentration of drug post-dose. Plasma Cmax was determined on Day 1 and Day 7 of MK-8876 dosing.</description>
        <time_frame>Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, and 24 hours post-dose on Days 1 and 7</time_frame>
        <population>All participants in Panels A, B, and E are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A: HCV GT3 MK-8876 150 mg</title>
            <description>Participants infected with HCV GT3 received 150 mg MK-8876 q.d. by mouth for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Panel B: HCV GT3 MK-8876 800 mg</title>
            <description>Participants infected with HCV GT3 received 800 mg MK-8876 q.d. by mouth for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>Panel E: HCV GT1a MK-8876 800 mg</title>
            <description>Participants infected with HCV GT1a received 800 mg MK-8876 q.d. by mouth for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) of MK-8876</title>
          <description>Cmax is a measure of the maximum plasma concentration of drug post-dose. Plasma Cmax was determined on Day 1 and Day 7 of MK-8876 dosing.</description>
          <population>All participants in Panels A, B, and E are included in the analysis.</population>
          <units>nM</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="177" spread="69.7"/>
                    <measurement group_id="O2" value="373" spread="29.7"/>
                    <measurement group_id="O3" value="773" spread="26.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="375" spread="70.7"/>
                    <measurement group_id="O2" value="1310" spread="12.3"/>
                    <measurement group_id="O3" value="1380" spread="22.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Plasma Concentration (C24hr) of MK-8876</title>
        <description>C24hr is a measure of the plasma drug concentration 24 hours post-dose (i.e., trough concentration). Plasma C24hr was determined on Day 1 and Day 7 of MK-8876 dosing.</description>
        <time_frame>24 hours post-dose on Days 1 and 7</time_frame>
        <population>All participants in Panels A, B, and E are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A: HCV GT3 MK-8876 150 mg</title>
            <description>Participants infected with HCV GT3 received 150 mg MK-8876 q.d. by mouth for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Panel B: HCV GT3 MK-8876 800 mg</title>
            <description>Participants infected with HCV GT3 received 800 mg MK-8876 q.d. by mouth for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>Panel E: HCV GT1a MK-8876 800 mg</title>
            <description>Participants infected with HCV GT1a received 800 mg MK-8876 q.d. by mouth for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Plasma Concentration (C24hr) of MK-8876</title>
          <description>C24hr is a measure of the plasma drug concentration 24 hours post-dose (i.e., trough concentration). Plasma C24hr was determined on Day 1 and Day 7 of MK-8876 dosing.</description>
          <population>All participants in Panels A, B, and E are included in the analysis.</population>
          <units>nM</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.1" spread="99.5"/>
                    <measurement group_id="O2" value="189" spread="17.1"/>
                    <measurement group_id="O3" value="370" spread="18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="173" spread="140.7"/>
                    <measurement group_id="O2" value="907" spread="17"/>
                    <measurement group_id="O3" value="869" spread="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Plasma Concentration (Tmax) of MK-8876</title>
        <description>Tmax is a measure of time required to reach the maximum plasma drug concentration post-dose. Plasma Tmax was calculated on Day 1 and Day 7 of MK-8876 dosing.</description>
        <time_frame>Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, and 24 hours post-dose on Days 1 and 7</time_frame>
        <population>All participants in Panels A, B, and E are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A: HCV GT3 MK-8876 150 mg</title>
            <description>Participants infected with HCV GT3 received 150 mg MK-8876 q.d. by mouth for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Panel B: HCV GT3 MK-8876 800 mg</title>
            <description>Participants infected with HCV GT3 received 800 mg MK-8876 q.d. by mouth for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>Panel E: HCV GT1a MK-8876 800 mg</title>
            <description>Participants infected with HCV GT1a received 800 mg MK-8876 q.d. by mouth for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Plasma Concentration (Tmax) of MK-8876</title>
          <description>Tmax is a measure of time required to reach the maximum plasma drug concentration post-dose. Plasma Tmax was calculated on Day 1 and Day 7 of MK-8876 dosing.</description>
          <population>All participants in Panels A, B, and E are included in the analysis.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="6"/>
                    <measurement group_id="O2" value="6" lower_limit="4" upper_limit="6"/>
                    <measurement group_id="O3" value="4" lower_limit="4" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="4" upper_limit="6"/>
                    <measurement group_id="O2" value="4" lower_limit="2" upper_limit="6"/>
                    <measurement group_id="O3" value="4" lower_limit="2" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Terminal Plasma Half-life (t½) of MK-8876</title>
        <description>t½ is the time required for the maximum plasma drug concentration to reduce by 50% post-dose. Plasma t½ was determined on Day 7 of MK-8876 dosing.</description>
        <time_frame>Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, and 24 hours post-dose on Day 7</time_frame>
        <population>All participants in Panels A, B, and E are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Panel A: HCV GT3 MK-8876 150 mg</title>
            <description>Participants infected with HCV GT3 received 150 mg MK-8876 q.d. by mouth for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Panel B: HCV GT3 MK-8876 800 mg</title>
            <description>Participants infected with HCV GT3 received 800 mg MK-8876 q.d. by mouth for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>Panel E: HCV GT1a MK-8876 800 mg</title>
            <description>Participants infected with HCV GT1a received 800 mg MK-8876 q.d. by mouth for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Terminal Plasma Half-life (t½) of MK-8876</title>
          <description>t½ is the time required for the maximum plasma drug concentration to reduce by 50% post-dose. Plasma t½ was determined on Day 7 of MK-8876 dosing.</description>
          <population>All participants in Panels A, B, and E are included in the analysis.</population>
          <units>Hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.1" spread="20.5"/>
                    <measurement group_id="O2" value="140" spread="24.2"/>
                    <measurement group_id="O3" value="62.5" spread="66.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to Day 21</time_frame>
      <desc>All AE data for GT1a and GT3 participants treated with MK-8876 800 mg were combined.</desc>
      <group_list>
        <group group_id="E1">
          <title>MK-8876 150 mg</title>
          <description>All HCV GT3 participants treated with MK-8876 150 mg are included.</description>
        </group>
        <group group_id="E2">
          <title>MK-8876 800 mg</title>
          <description>All HCV GT1a and GT3 participants treated with MK-8876 800 mg are included.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA v. 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

